What Is Aldara Cream and What Is It Used For?

Aldara is the brand name for imiquimod 5% cream, a prescription topical medication that works by stimulating your own immune system to fight certain skin conditions. It holds FDA approval for three uses: external genital and perianal warts caused by HPV, actinic keratoses (rough, scaly patches from sun damage that can become cancerous), and superficial basal cell carcinoma. Unlike a cream that directly kills abnormal cells or a virus, Aldara essentially sounds an alarm that recruits your body’s immune defenses to the application site, which makes it unusual among dermatological treatments.

How Aldara Works

Imiquimod belongs to a class of compounds called imidazoquinolines. When you apply Aldara to the skin, the active ingredient binds to a receptor called Toll-like receptor 7 (TLR7) on certain immune cells, particularly a type of dendritic cell and macrophages. That binding triggers those cells to release a cascade of signaling molecules, including interferon-alpha, tumor necrosis factor-alpha, and interleukin-12.¹ Think of it as flipping on a floodlight: the immune system suddenly “sees” what’s happening on the treated patch of skin and mobilizes a response.

The practical result is a surge of immune cells into the treated area. Research on basal cell carcinomas treated with imiquimod found that inflammatory infiltrate developed within three to five days of starting treatment, consisting of macrophages and lymphocytes that invaded in and around the tumor. Tumor cells also became more vulnerable to programmed cell death, partly through reduced expression of a survival protein called Bcl-2.² In squamous cell carcinomas, treated tumors showed dense T-cell infiltrates, with those T cells producing more of the molecules that kill abnormal cells and less of the molecules that suppress immune activity.³ At higher concentrations, imiquimod can also directly trigger apoptosis in tumor cells through a separate pathway involving caspase activation.⁴

This immune-based approach is both the cream’s greatest strength and its most important limitation. It works best on superficial, accessible lesions where the immune system can reach and overwhelm the target. Deep or aggressive tumors are a different story, which is why Aldara’s approved cancer indications are limited to shallow growths.

Genital and Perianal Warts

Aldara’s first FDA approval, granted in 1997, was for external genital and perianal warts caused by human papillomavirus. It was originally developed as a potential antiviral agent during the search for new anti-herpes drugs, and its immune-stimulating properties turned out to be more therapeutically useful than any direct antiviral effect.⁵ For warts, the cream is typically applied three times per week at bedtime and washed off after about six to ten hours, continuing for up to 16 weeks or until warts clear.⁶

In a controlled trial, half of patients using 5% imiquimod cream achieved complete clearance of all treated warts, compared with about 11% in the placebo group.⁷ That 50% clearance rate is decent but not overwhelming, and recurrence remains a real challenge. Because Aldara treats the visible warts but does not eradicate HPV from the body, new warts can appear after treatment ends. Low patient compliance and high recurrence are acknowledged problems in the literature.⁸

The main practical advantage over in-office treatments like cryotherapy (freezing) is convenience: you apply it yourself at home, there are no clinic visits for each wart, and it is substantially less painful. A head-to-head trial found that cryotherapy cleared warts completely in about 87% of patients versus 69% for imiquimod, but cryotherapy was significantly more painful, and recurrence rates between the two were not statistically different.⁹ For many patients, the trade-off of slightly lower initial clearance in exchange for self-treatment at home is worth it.

Actinic Keratoses

Actinic keratoses are rough, scaly patches that develop on sun-exposed skin after years of ultraviolet damage. They are considered precancerous because a small percentage can progress to squamous cell carcinoma. Aldara was approved for this indication in 2004, applied two to three times per week for 16 weeks on the face or scalp. The appeal is that it treats an entire “field” of sun-damaged skin rather than individual spots, potentially catching subclinical lesions you cannot see yet.

A 12-day treatment course showed complete clearance in about 52% of patients and partial response in roughly 75%.¹⁰ Those numbers vary across studies depending on treatment duration and how aggressive the regimen is. But how does Aldara stack up against the main alternative, 5-fluorouracil (5-FU) cream? The evidence here is fairly consistent: 5-FU tends to outperform imiquimod. A large randomized trial published in the New England Journal of Medicine found that at 12 months after treatment, about 75% of patients treated with fluorouracil remained free of treatment failure, compared with about 54% for imiquimod.¹¹ Another comparison found that 5-FU reduced the total keratosis count by 94% versus 66% for imiquimod, and achieved complete clearance in 84% versus 24% of patients by 24 weeks.¹²

That said, imiquimod at a lower concentration (3.75%) performed comparably to a lower-strength 5-FU (4%) in a split-face study, with no significant difference in clearance, tolerability, or cosmetic outcome.¹³ The choice often comes down to your dermatologist’s preference, the extent of your sun damage, and how much skin irritation you are willing to tolerate. In practice, many dermatologists still reach for 5-FU first for widespread actinic keratoses, reserving imiquimod for patients who cannot tolerate 5-FU or who prefer a less aggressive regimen.

Superficial Basal Cell Carcinoma

Basal cell carcinoma is the most common type of skin cancer, and the superficial subtype sits in the uppermost layer of skin, making it shallow enough for a topical approach. Aldara received approval for superficial BCC in 2004, applied five times per week for six weeks. Two large trials showed composite clearance rates around 73–75% with that schedule, compared with just 2% for placebo.¹⁴ Interestingly, data from those trials showed that stronger local skin reactions during treatment, including redness, erosion, and crusting, predicted higher clearance rates.¹⁵ The more inflamed your skin gets, the more aggressively the immune system is working, which paradoxically means the nasty-looking reaction is a sign the treatment is doing its job.

Long-term follow-up data tells a more nuanced story. At five years, a study of various BCC subtypes found that superficial BCCs treated with imiquimod maintained a 100% clearance rate, but nodular BCCs dropped to 75% and infiltrative BCCs to 60%.¹⁶ Surgical excision remains the gold standard, particularly for deeper or more aggressive subtypes. A secondary analysis of a randomized trial comparing superficial curettage plus imiquimod versus surgical excision for nodular BCC found that the five-year probability of remaining free from treatment failure was about 78% after the curettage-plus-imiquimod approach, compared with about 98% after surgery.¹⁷ For many patients with superficial BCC, especially those in locations where a scar is undesirable or who are poor surgical candidates, Aldara is a reasonable alternative. But for nodular or infiltrative BCC, surgery is strongly preferred.

Off-Label Uses

Dermatologists have used imiquimod for a broader range of conditions than the three FDA-approved indications. The literature includes reports of its use against common warts, molluscum contagiosum, and certain other viral and neoplastic skin conditions.¹⁸ One of the more studied off-label uses is lentigo maligna, a type of melanoma in situ that appears as a slowly growing brown patch, usually on the face of older adults. Surgery is the standard treatment, but lentigo maligna can cover large areas on cosmetically sensitive regions where wide excision creates significant disfigurement.

A randomized trial tested imiquimod alone versus imiquimod combined with tazarotene for lentigo maligna, finding complete clinical responses in 64% with monotherapy and 78% with the combination, followed by conservative staged excisions.¹⁹ A systematic review of long-term outcomes reported clinical clearance rates ranging from about 64% to 97%, with recurrence rates between 0% and 21%.²⁰ The wide spread in those numbers reflects differences in study design and follow-up duration, but the general pattern is encouraging enough that imiquimod is considered a viable option for patients who cannot or will not undergo surgery for lentigo maligna.

What the Side Effects Actually Feel Like

If you have never used Aldara, the local skin reactions can be alarming. The treated area typically becomes red, swollen, and may develop erosions, crusting, or scabbing. Some patients describe it as looking like a severe sunburn or a raw wound. This is not an allergic reaction or a sign something has gone wrong. It is the intended immune response, and as noted above in the BCC data, worse-looking reactions tend to correlate with better treatment outcomes.

Beyond the local irritation, a smaller number of patients develop flu-like symptoms: fever, muscle aches, fatigue, and general malaise. These systemic effects are driven by the same cytokine cascade that produces the local response. In most patients who experienced these symptoms, they appeared within 7 to 11 days into the treatment cycle.²¹ The symptoms are generally mild and resolve on their own, but occasionally they can be striking. One case report described a young man who developed recurrent fever, muscle pain, and malaise within hours of each application to genital warts located on non-keratinized mucosal tissue, where higher absorption led to more pronounced systemic immune activation.²² If you develop significant systemic symptoms, your prescriber may reduce the application frequency or build in rest periods.

One rarer concern worth mentioning: Aldara has been reported to trigger or worsen psoriasis. The immune pathways it activates overlap with those involved in psoriatic inflammation, and in patients with existing psoriasis or a genetic predisposition, the cream can set off a flare at or even away from the application site.²³ If you have a history of psoriasis, make sure your dermatologist knows before you start treatment.

Organ Transplant Recipients

People who have received organ transplants take immunosuppressive drugs for the rest of their lives to prevent rejection, and those drugs dramatically raise the risk of skin cancers, particularly squamous cell carcinoma and actinic keratoses. This creates a tricky treatment dilemma: you need to boost the local immune response against precancerous skin lesions without triggering a systemic immune reaction that could threaten the transplanted organ.

The evidence on Aldara in this population is cautiously positive. A multicentre randomized trial in kidney, heart, and liver transplant patients found that imiquimod achieved complete clearance of actinic keratoses in about 62% of treated patients versus 0% with placebo. No graft rejections or trends toward deteriorating graft function were detected, and clearance was confirmed histologically in all cases.²⁴ A smaller case series of six transplant patients reported that five of six achieved complete clearance after 12 to 16 weeks, with stable graft-related laboratory values and no changes to immunosuppressive therapy throughout.²⁵ A broader review of the literature concluded that results in transplant patients are reassuring regarding both safety and efficacy.²⁶

These findings matter because transplant recipients develop skin cancers at dramatically higher rates than the general population, and they often develop many lesions over large areas of sun-exposed skin. A field-directed treatment like Aldara that can address widespread precancerous changes without systemic immune effects fills a genuine clinical need for this group.

Pregnancy and Aldara

Genital warts can proliferate during pregnancy due to hormonal and immune changes, and treating them before delivery is sometimes necessary to reduce the risk of transmission to the newborn or complications during vaginal birth. Aldara is categorized as a second-line option in pregnancy, meaning it is considered likely safe but not a first choice.²⁷ A report of four pregnant women treated with imiquimod for anogenital warts found no adverse fetal outcomes, neonatal abnormalities, or complications in the postpartum period, even in cases of extensive warts.²⁸ Four cases is not a large enough sample to make broad safety claims, so the conservative approach, treating only when the clinical benefit clearly justifies the limited data, is the standard guidance.

Combining Aldara with Other Treatments

Because Aldara works through the immune system rather than direct cell destruction, researchers have explored whether pairing it with other therapies could boost results. One of the more studied combinations is imiquimod with photodynamic therapy (PDT), where a light-sensitizing agent is applied to the skin and then activated with a specific wavelength of light. A meta-analysis found that combining PDT with imiquimod significantly improved complete clearance rates for actinic keratoses compared with either treatment alone.²⁹ The logic is straightforward: PDT directly destroys abnormal cells while imiquimod recruits the immune system to clean up what is left and address subclinical disease in the surrounding field.

In cutaneous squamous cell carcinoma, a study found that the combination of imiquimod and PDT outperformed either treatment alone, with the combo group showing roughly double the CD8+ T cells (the immune cells that kill abnormal cells) and the highest number of apoptotic tumor cells.³⁰ These combination protocols are not yet standard practice everywhere, but they represent a growing area of interest, particularly for patients with extensive sun damage and multiple lesions who need aggressive field treatment.

Cost Considerations

Aldara can be expensive without insurance, and even with coverage, copays for branded imiquimod cream can be substantial. Generic imiquimod 5% is available and more affordable, though prices vary widely by pharmacy and region. One area where Aldara has a financial edge is compared with in-clinic procedures that require repeated office visits. A cost-effectiveness analysis comparing imiquimod with methyl aminolevulinate-based photodynamic therapy (MAL-PDT) for actinic keratoses found that imiquimod cost about £174 less per year (in 2006 UK values), with a 75% probability of being cost-effective at standard willingness-to-pay thresholds.³¹ The at-home nature of Aldara means fewer visits, less time off work, and no procedural costs, which for many patients offsets the sticker price of the cream itself.

If your pharmacist hands you generic imiquimod instead of branded Aldara, the active ingredient is identical. The vehicle (the cream base) may differ slightly between manufacturers, and some patients report differences in texture or absorption, but the clinical evidence does not suggest meaningful differences in efficacy between brand and generic formulations for any of the approved indications.

How the Application Schedule Varies by Condition

One common source of confusion is that Aldara is not a one-size-fits-all prescription. The frequency and duration of application differ substantially depending on what you are treating.⁶

• Genital warts: Three times per week (e.g. Monday, Wednesday, Friday) for up to 16 weeks. Applied at bedtime and washed off six to ten hours later.
• Actinic keratoses: Two times per week for 16 weeks, applied to a defined treatment area on the face or scalp. Some protocols use shorter, more intensive courses.
• Superficial BCC: Five times per week for six weeks, applied to the tumor and a small margin of surrounding skin.

The cream should be applied in a thin layer, just enough to cover the treatment area, and rubbed in until it disappears. Occlusion (covering with a bandage) is generally not recommended unless your dermatologist specifically instructs it, because trapping the cream against the skin can intensify the inflammatory reaction beyond what is helpful. You should also avoid sexual contact while the cream is on genital skin, as it can weaken condoms and diaphragms. Washing your hands thoroughly after application prevents accidentally spreading the immune-stimulating effect to your eyes, lips, or other sensitive mucous membranes.

If the local reaction becomes too intense, most dermatologists will recommend a “rest period” of several days before resuming treatment rather than stopping entirely. Skipping too many applications can reduce effectiveness, but pushing through severe erosions and pain is counterproductive and can lead to scarring. The goal is a brisk but manageable inflammatory response.